Weinmann P, Moretti J L
Servive de Médecine Nucléaire, Hôpital Avicenne, Bobigny, France.
Nucl Med Commun. 1999 Jul;20(7):623-5. doi: 10.1097/00006231-199907000-00005.
It has been suggested that metoclopramide may reduce artefacts caused by intestinal activity super-imposed on myocardial uptake of MIBI SPET. This study compared the abdominal activity of MIBI in patients given metoclopramide versus a control group. Forty-seven patients with normal scintigrams or with completely normal inferior wall perfusion underwent rest 201T1 + stress MIBI testing. Twenty-four patients arbitrarily received 10 mg metoclopramide orally 45 min before the MIBI injection and 23 patients no metoclopramide. The patients were divided according to the stress performed: 23 patients had exercise and 24 patients dipyridamole infusion, and a comparison was done between patients with metoclopramide and those without. Myocardial and abdominal activity were assessed at 15 and 60 min on three separate projections and the mean myocardium-to-abdomen ratios were computed. The ratio was 1.30 +/- 0.19 and 1.57 +/- 0.23 in the patients with exercise and metoclopramide versus 1.36 +/- 0.18 and 1.64 +/- 0.23 in the patients with exercise alone at 15 and 60 min respectively. The ratio was 0.92 +/- 0.13 and 1.21 +/- 0.21 in the patients with dipyridamole infusion and metoclopramide versus 1.02 +/- 0.17 and 1.33 +/- 0.16 in the patients with dipyridamole alone at 15 and 60 min respectively. These differences were not statistically significant. In conclusion, metoclopramide has no effect on MIBI abdominal activity and is not recommended in routine practice.
有人提出，甲氧氯普胺可能会减少肠道活动叠加在心肌摄取心肌灌注显像剂锝-99m甲氧基异丁基异腈单光子发射计算机断层扫描（MIBI SPET）上所导致的伪影。本研究比较了接受甲氧氯普胺治疗的患者与对照组患者腹部的MIBI活性。47例闪烁扫描正常或下壁灌注完全正常的患者接受了静息态铊-201 + 负荷态MIBI检查。24例患者在注射MIBI前45分钟随机口服10毫克甲氧氯普胺，23例患者未服用甲氧氯普胺。患者根据所进行的负荷试验进行分组：23例患者进行运动试验，24例患者进行双嘧达莫静脉输注试验，并对服用甲氧氯普胺的患者和未服用的患者进行比较。在三个不同的投影方向上于15分钟和60分钟时评估心肌和腹部活性，并计算平均心肌与腹部的比值。在进行运动试验且服用甲氧氯普胺的患者中，该比值在15分钟和60分钟时分别为1.30±0.19和1.57±0.23，而仅进行运动试验的患者中该比值分别为1.36±0.18和1.64±0.23。在进行双嘧达莫静脉输注试验且服用甲氧氯普胺的患者中，该比值在15分钟和60分钟时分别为0.92±0.13和1.21±0.21，而仅进行双嘧达莫静脉输注试验的患者中该比值分别为1.02±0.17和1.33±0.16。这些差异无统计学意义。总之，甲氧氯普胺对MIBI腹部活性无影响，不建议在常规实践中使用。
